Toward illness phase-specific pharmacotherapy for schizophrenia

Affiliations

¹ Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Neurobiology, Yale University School of Medicinem, New Haven, Connecticut; Yale-New Haven Hospital, New Haven, Connecticut. Electronic address: john.krystal@yale.edu.
² Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Psychology, Yale University School of Medicine; New Haven, Connecticut; Abraham Ribicoff Research Facilities, Connecticut Mental Health, New Haven, Connecticut.

Comment

John H Krystal et al. Biol Psychiatry. 2015.

. 2015 Dec 1;78(11):738-40.

doi: 10.1016/j.biopsych.2015.08.017.

¹ Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Neurobiology, Yale University School of Medicinem, New Haven, Connecticut; Yale-New Haven Hospital, New Haven, Connecticut. Electronic address: john.krystal@yale.edu.
² Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Psychology, Yale University School of Medicine; New Haven, Connecticut; Abraham Ribicoff Research Facilities, Connecticut Mental Health, New Haven, Connecticut.

No abstract available

Comment on

Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
Kinon BJ, Millen BA, Zhang L, McKinzie DL. Kinon BJ, et al. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19. Biol Psychiatry. 2015. PMID: 25890643